The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Latest NewsMORE >>

The approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy has been expanded by the FDA to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia, according to Novartis, the manufacturer of eltrombopag. Eltrombopag was also granted a breakthrough therapy designation as a counter measure for hematopoietic sub-syndrome of acute radiation syndrome.

Latest JournalAll Journals >>

Targeted Therapies in Oncology November 2018
Targeted Therapies in Oncology
MORE >>
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.